Editas Medicine Inc
EDIT
查看详细走势图
1.820USD
+0.155+9.31%
收盘 02/06, 16:00（美东）报价延迟15分钟
169.74M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+9.31%
5天
-8.54%
1月
-14.95%
6月
-28.06%
今年开始到现在
-11.22%
1年
+40.00%
查看详细走势图
TradingKey Editas Medicine Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Editas Medicine Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名121/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价5.21。中期看，股价处于下降通道。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Editas Medicine Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Editas Medicine Inc亮点
亮点风险
Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.
业绩高增长
公司营业收入稳步增长，连续3年增长63.93%
业绩增长期
公司处于发展阶段，最新年度总收入32.31M美元
估值高估
公司最新PE估值-0.78，处于3年历史高位
机构加仓
最新机构持股46.01M股，环比增加0.01%
默里·斯塔尔持仓
明星投资者默里·斯塔尔持仓，最新持仓市值31.67K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.28
分析师目标
根据
14
位分析师
买入
评级
5.214
目标均价
+213.17%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Editas Medicine Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Editas Medicine Inc简介
Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.
公司代码EDIT
公司Editas Medicine Inc
CEOO'Neill (Gilmore Neil)
网址https://www.editasmedicine.com/
相关品种
